Biotech Values

[DewDiligence]

BSX acquires BTG.L for $4.24B in cash—a 37% premium:

https://www.wsj.com/articles/boston-scientific-acquires-u-k-s-btg-for-4-2-billion-1542713291

Boston Scientific said BTG’s interventional portfolio would boost its capabilities in areas such as cancer and pulmonary embolism… BTG’s PneumRx product, for example, is a tiny coil inserted into the lung’s airways to treat emphysema.

…Boston Scientific said it hadn’t yet decided what to do in the long term with BTG’s pharmaceuticals business, which is focused on antidote products and accounts for about a third of its total revenue. The biggest-selling product in that portfolio, CroFab, treats rattlesnake bites.